Bugworks Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 30
Employees
  • Latest Deal Type
  • Series B1
  • Latest Deal Amount
  • $16M
Latest Deal Amount
  • Investors
  • 20

Bugworks General Information

Description

Developer of a novel class of antibiotic drugs intended to tackle the problem of antimicrobial resistance. The company's platform is producing multiple broad-spectrum assets (dual target, covering ESKAPE spectrum of pathogens) with applications in Hospital, Community infections and also in BioDefense (against deadly bioterror pathogens) and also has a vibrant pipeline in Immuno-Oncology by designing best-in-class small-molecule Adenosine A2AR/A2BR antagonists, which are being tested both as stand-alone and combination (with PD1/PDL1, CTLA4) therapies, for various solid tumours, enabling healthcare providers to reduce efflux mediated drug resistance.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • 13962 Pierce Road
  • Saratoga, CA 95070
  • United States
+1 (818) 000-0000

Bugworks Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Bugworks Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series B1) 08-Nov-2021 $16M 000.00 0000 Completed Clinical Trials - Phase 1
7. Early Stage VC (Series B) 23-Apr-2020 00.000 000.00 000.00 Completed Clinical Trials - Phase 1
6. Grant 08-Dec-2019 000 000.00 Completed Clinical Trials - Phase 1
5. Early Stage VC (Series A) 13-Aug-2018 000 000.00 0000 Completed Product In Beta Test
4. Grant 24-Jul-2017 00.00 00.00 Completed Product In Beta Test
3. Seed Round 20-Nov-2015 00.00 00.00 00.00 Completed Product In Beta Test
2. Accelerator/Incubator 19-Jul-2014 Completed Product In Beta Test
1. Grant 04-Feb-2014 $500K Completed Product In Beta Test
To view Bugworks’s complete valuation and funding history, request access »

Bugworks Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B1 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B 0,000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series A2 000,000 00.000000 00 00.00 00.00 00 00.00 0.00
Series A1 0,000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series A 3,537,819 $0.000100 1% $1.7 $1.7 1x $1.7 11.05%
Seed 4,126,230 $0.000100 $0.63 $0.63 1x $0.63 12.88%
To view Bugworks’s complete cap table history, request access »

Bugworks Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a novel class of antibiotic drugs intended to tackle the problem of antimicrobial resistance. The company's
Drug Discovery
Saratoga, CA
30 As of 2021
000.00
000 0000-00-00
00000000000 000.00

00000000

oris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate ve
000000000000000
Watertown, MA
00 As of 0000
00000
000 0000-00-00
000000&0 00000

0000000

cididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamc
0000 000000000
Brighton, United Kingdom
00 As of 0000
0000
00000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Bugworks Competitors (18)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Tetraphase Pharmaceuticals Formerly VC-backed Watertown, MA 00 00000 000000&0 00000
0000000 000000 Formerly PE-Backed Brighton, United Kingdom 00 0000 00000000 0000
0000000 0000000000 Formerly VC-backed Waltham, MA 00 00000 0&0
00000 000000000000 Formerly VC-backed Cambridge, MA 000 00000 000000000 00000
000000000 Venture Capital-Backed Basel, Switzerland 00 000.00 00000000000 000.00
You’re viewing 5 of 18 competitors. Get the full list »

Bugworks Patents

Bugworks Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2021519314-A Oxazolidinone antibiotic compound and preparation method Pending 28-Mar-2018 0000000000
EP-3774790-A1 Oxazolidinone antibiotic compounds and process of preparation Pending 28-Mar-2018 0000000000
US-20210008078-A1 Oxazolidinone antibiotic compounds and process of preparation Pending 28-Mar-2018 0000000000
EP-3717490-A1 Anti-bacterial heterocyclic compounds and their synthesis Pending 29-Nov-2017 0000000000
US-20210070772-A1 Anti-bacterial heterocyclic compounds and their synthesis Pending 29-Nov-2017 C07D498/04
To view Bugworks’s complete patent history, request access »

Bugworks Executive Team (7)

Name Title Board Seat Contact Info
Anand Anandkumar Ph.D Co-Founder, Chief Executive Officer, Managing Director & Board Member
V. Balasubramanian Ph.D Co-Founder, President, Chief Operating Officer & Board Member
Santanu Datta Ph.D Co-Founder, Chief Scientific Officer & Board Member
Shahul Hameed Chief Product Officer
You’re viewing 4 of 7 executive team members. Get the full list »

Bugworks Board Members (9)

Name Representing Role Since
Abraham Van Wyk Self Board Observer 000 0000
Anand Anandkumar Ph.D Bugworks Co-Founder, Chief Executive Officer, Managing Director & Board Member 000 0000
Atsushi Usami Ph.D The University of Tokyo Edge Capital Board Member 000 0000
Kiran Mysore Self Board Observer 000 0000
Pranav Pai Self Board Observer 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Bugworks Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Bugworks Investors (20)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Glentec International Corporation Minority 000 0000 000000 0
Kotak Investment Advisors Asset Manager Minority 000 0000 000000 0
Lightrock (Bangalore) Venture Capital Minority 000 0000 000000 0
Global Brain Venture Capital Minority 000 0000 000000 0
3one4 Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 20 investors. Get the full list »